nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP1A2—Carmustine—melanoma	0.0681	0.176	CbGbCtD
Ziprasidone—CYP1A2—Vemurafenib—melanoma	0.0538	0.139	CbGbCtD
Ziprasidone—CYP3A4—Temozolomide—melanoma	0.0515	0.133	CbGbCtD
Ziprasidone—CYP2D6—Vemurafenib—melanoma	0.0444	0.114	CbGbCtD
Ziprasidone—CYP1A2—Dacarbazine—melanoma	0.0413	0.106	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.0331	0.0853	CbGbCtD
Ziprasidone—CYP3A7—Docetaxel—melanoma	0.0331	0.0853	CbGbCtD
Ziprasidone—CYP3A4—Vemurafenib—melanoma	0.0282	0.0727	CbGbCtD
Ziprasidone—CYP3A5—Docetaxel—melanoma	0.0248	0.064	CbGbCtD
Ziprasidone—HTR1D—meninx—melanoma	0.0183	0.196	CbGeAlD
Ziprasidone—DRD5—eyelid—melanoma	0.0166	0.178	CbGeAlD
Ziprasidone—CYP3A4—Docetaxel—melanoma	0.00968	0.025	CbGbCtD
Ziprasidone—CHRM5—skin epidermis—melanoma	0.00465	0.0498	CbGeAlD
Ziprasidone—H1F0—hair follicle—melanoma	0.00286	0.0306	CbGeAlD
Ziprasidone—HTR2A—hindlimb—melanoma	0.00216	0.0232	CbGeAlD
Ziprasidone—HTR1B—blood vessel—melanoma	0.00215	0.023	CbGeAlD
Ziprasidone—HTR1D—blood vessel—melanoma	0.00208	0.0223	CbGeAlD
Ziprasidone—H1F0—neck—melanoma	0.00192	0.0206	CbGeAlD
Ziprasidone—HTR2A—appendage—melanoma	0.00186	0.0199	CbGeAlD
Ziprasidone—HTR7—endothelium—melanoma	0.0018	0.0192	CbGeAlD
Ziprasidone—HTR7—blood vessel—melanoma	0.00166	0.0177	CbGeAlD
Ziprasidone—CHRM5—eye—melanoma	0.00166	0.0177	CbGeAlD
Ziprasidone—CHRM5—skin of body—melanoma	0.00144	0.0154	CbGeAlD
Ziprasidone—H1F0—retina—melanoma	0.00142	0.0152	CbGeAlD
Ziprasidone—HTR1E—head—melanoma	0.00137	0.0147	CbGeAlD
Ziprasidone—H1F0—skin of body—melanoma	0.00124	0.0133	CbGeAlD
Ziprasidone—CHRM4—head—melanoma	0.0012	0.0129	CbGeAlD
Ziprasidone—HTR7—neck—melanoma	0.00118	0.0127	CbGeAlD
Ziprasidone—H1F0—mammalian vulva—melanoma	0.00113	0.0121	CbGeAlD
Ziprasidone—HTR2A—endothelium—melanoma	0.00112	0.012	CbGeAlD
Ziprasidone—DRD3—head—melanoma	0.00112	0.012	CbGeAlD
Ziprasidone—HTR1D—eye—melanoma	0.00111	0.0118	CbGeAlD
Ziprasidone—HTR6—head—melanoma	0.00108	0.0115	CbGeAlD
Ziprasidone—DRD5—head—melanoma	0.00105	0.0112	CbGeAlD
Ziprasidone—HTR2A—blood vessel—melanoma	0.00103	0.0111	CbGeAlD
Ziprasidone—CHRM5—head—melanoma	0.00094	0.0101	CbGeAlD
Ziprasidone—ADRA1B—head—melanoma	0.000859	0.0092	CbGeAlD
Ziprasidone—DRD2—eye—melanoma	0.000833	0.00892	CbGeAlD
Ziprasidone—DRD2—retina—melanoma	0.000826	0.00884	CbGeAlD
Ziprasidone—H1F0—head—melanoma	0.000811	0.00868	CbGeAlD
Ziprasidone—DRD1—head—melanoma	0.000801	0.00857	CbGeAlD
Ziprasidone—HTR3A—head—melanoma	0.000773	0.00828	CbGeAlD
Ziprasidone—HTR2A—neck—melanoma	0.000739	0.00791	CbGeAlD
Ziprasidone—HRH1—eye—melanoma	0.000658	0.00704	CbGeAlD
Ziprasidone—HTR1B—head—melanoma	0.000649	0.00695	CbGeAlD
Ziprasidone—CHRM2—head—melanoma	0.000645	0.00691	CbGeAlD
Ziprasidone—ADRA2C—mammalian vulva—melanoma	0.000643	0.00688	CbGeAlD
Ziprasidone—HTR1D—head—melanoma	0.000628	0.00672	CbGeAlD
Ziprasidone—HTR2C—head—melanoma	0.000622	0.00666	CbGeAlD
Ziprasidone—SLC6A4—head—melanoma	0.00059	0.00631	CbGeAlD
Ziprasidone—CHRM1—head—melanoma	0.000587	0.00629	CbGeAlD
Ziprasidone—H1F0—lymph node—melanoma	0.000568	0.00608	CbGeAlD
Ziprasidone—HTR2A—eye—melanoma	0.00055	0.00588	CbGeAlD
Ziprasidone—HTR2A—retina—melanoma	0.000545	0.00583	CbGeAlD
Ziprasidone—CHRM3—head—melanoma	0.000526	0.00563	CbGeAlD
Ziprasidone—HTR1A—head—melanoma	0.000523	0.0056	CbGeAlD
Ziprasidone—HRH1—mammalian vulva—melanoma	0.000522	0.00559	CbGeAlD
Ziprasidone—ADRA2A—mammalian vulva—melanoma	0.000513	0.00549	CbGeAlD
Ziprasidone—HTR7—head—melanoma	0.0005	0.00536	CbGeAlD
Ziprasidone—ADRA1A—head—melanoma	0.000483	0.00517	CbGeAlD
Ziprasidone—DRD2—head—melanoma	0.000473	0.00506	CbGeAlD
Ziprasidone—KCNH2—head—melanoma	0.000466	0.00499	CbGeAlD
Ziprasidone—ADRA2C—head—melanoma	0.00046	0.00492	CbGeAlD
Ziprasidone—Hypoaesthesia—Temozolomide—melanoma	0.000441	0.00177	CcSEcCtD
Ziprasidone—Pharyngitis—Temozolomide—melanoma	0.00044	0.00177	CcSEcCtD
Ziprasidone—Chills—Dactinomycin—melanoma	0.000439	0.00177	CcSEcCtD
Ziprasidone—Urinary tract disorder—Temozolomide—melanoma	0.000437	0.00176	CcSEcCtD
Ziprasidone—Oedema peripheral—Temozolomide—melanoma	0.000436	0.00176	CcSEcCtD
Ziprasidone—Connective tissue disorder—Temozolomide—melanoma	0.000435	0.00175	CcSEcCtD
Ziprasidone—Lethargy—Docetaxel—melanoma	0.000435	0.00175	CcSEcCtD
Ziprasidone—Urethral disorder—Temozolomide—melanoma	0.000434	0.00175	CcSEcCtD
Ziprasidone—Alopecia—Dactinomycin—melanoma	0.000433	0.00174	CcSEcCtD
Ziprasidone—Eye disorder—Carmustine—melanoma	0.000428	0.00172	CcSEcCtD
Ziprasidone—Hyponatraemia—Docetaxel—melanoma	0.000428	0.00172	CcSEcCtD
Ziprasidone—Visual impairment—Temozolomide—melanoma	0.000427	0.00172	CcSEcCtD
Ziprasidone—Erythema—Dactinomycin—melanoma	0.000426	0.00171	CcSEcCtD
Ziprasidone—Pain in extremity—Docetaxel—melanoma	0.000426	0.00171	CcSEcCtD
Ziprasidone—Anaemia—Bleomycin—melanoma	0.000423	0.0017	CcSEcCtD
Ziprasidone—Diarrhoea—Vemurafenib—melanoma	0.000421	0.00169	CcSEcCtD
Ziprasidone—Eye disorder—Temozolomide—melanoma	0.000414	0.00167	CcSEcCtD
Ziprasidone—Tinnitus—Temozolomide—melanoma	0.000413	0.00166	CcSEcCtD
Ziprasidone—Cardiac disorder—Temozolomide—melanoma	0.000411	0.00165	CcSEcCtD
Ziprasidone—Arrhythmia—Carmustine—melanoma	0.000409	0.00165	CcSEcCtD
Ziprasidone—Leukopenia—Bleomycin—melanoma	0.000409	0.00165	CcSEcCtD
Ziprasidone—Dizziness—Vemurafenib—melanoma	0.000407	0.00164	CcSEcCtD
Ziprasidone—Alopecia—Carmustine—melanoma	0.000405	0.00163	CcSEcCtD
Ziprasidone—Angiopathy—Temozolomide—melanoma	0.000402	0.00162	CcSEcCtD
Ziprasidone—Mental disorder—Carmustine—melanoma	0.000402	0.00162	CcSEcCtD
Ziprasidone—Ataxia—Docetaxel—melanoma	0.0004	0.00161	CcSEcCtD
Ziprasidone—Immune system disorder—Temozolomide—melanoma	0.0004	0.00161	CcSEcCtD
Ziprasidone—Mediastinal disorder—Temozolomide—melanoma	0.000399	0.00161	CcSEcCtD
Ziprasidone—Malnutrition—Carmustine—melanoma	0.000399	0.0016	CcSEcCtD
Ziprasidone—Erythema—Carmustine—melanoma	0.000399	0.0016	CcSEcCtD
Ziprasidone—Cough—Bleomycin—melanoma	0.000399	0.0016	CcSEcCtD
Ziprasidone—Chills—Temozolomide—melanoma	0.000397	0.0016	CcSEcCtD
Ziprasidone—Dehydration—Docetaxel—melanoma	0.000396	0.00159	CcSEcCtD
Ziprasidone—Anaemia—Dactinomycin—melanoma	0.000394	0.00158	CcSEcCtD
Ziprasidone—Liver function test abnormal—Docetaxel—melanoma	0.000393	0.00158	CcSEcCtD
Ziprasidone—Vomiting—Vemurafenib—melanoma	0.000392	0.00157	CcSEcCtD
Ziprasidone—Alopecia—Temozolomide—melanoma	0.000391	0.00157	CcSEcCtD
Ziprasidone—Myalgia—Bleomycin—melanoma	0.000389	0.00157	CcSEcCtD
Ziprasidone—Chest pain—Bleomycin—melanoma	0.000389	0.00157	CcSEcCtD
Ziprasidone—Orthostatic hypotension—Docetaxel—melanoma	0.000389	0.00156	CcSEcCtD
Ziprasidone—Rash—Vemurafenib—melanoma	0.000388	0.00156	CcSEcCtD
Ziprasidone—Mental disorder—Temozolomide—melanoma	0.000388	0.00156	CcSEcCtD
Ziprasidone—Dermatitis—Vemurafenib—melanoma	0.000388	0.00156	CcSEcCtD
Ziprasidone—Back pain—Carmustine—melanoma	0.000386	0.00155	CcSEcCtD
Ziprasidone—Headache—Vemurafenib—melanoma	0.000386	0.00155	CcSEcCtD
Ziprasidone—Erythema—Temozolomide—melanoma	0.000386	0.00155	CcSEcCtD
Ziprasidone—Malnutrition—Temozolomide—melanoma	0.000386	0.00155	CcSEcCtD
Ziprasidone—Breast disorder—Docetaxel—melanoma	0.000385	0.00155	CcSEcCtD
Ziprasidone—Cramp muscle—Docetaxel—melanoma	0.000383	0.00154	CcSEcCtD
Ziprasidone—Leukopenia—Dactinomycin—melanoma	0.000382	0.00153	CcSEcCtD
Ziprasidone—Nasopharyngitis—Docetaxel—melanoma	0.000381	0.00153	CcSEcCtD
Ziprasidone—Confusional state—Bleomycin—melanoma	0.000376	0.00151	CcSEcCtD
Ziprasidone—Vision blurred—Carmustine—melanoma	0.000376	0.00151	CcSEcCtD
Ziprasidone—Tremor—Carmustine—melanoma	0.000374	0.0015	CcSEcCtD
Ziprasidone—HRH1—head—melanoma	0.000373	0.004	CbGeAlD
Ziprasidone—Back pain—Temozolomide—melanoma	0.000373	0.0015	CcSEcCtD
Ziprasidone—Infection—Bleomycin—melanoma	0.000371	0.00149	CcSEcCtD
Ziprasidone—Anaemia—Carmustine—melanoma	0.000369	0.00148	CcSEcCtD
Ziprasidone—Dysphagia—Docetaxel—melanoma	0.000368	0.00148	CcSEcCtD
Ziprasidone—ADRA2A—head—melanoma	0.000367	0.00393	CbGeAlD
Ziprasidone—Agitation—Carmustine—melanoma	0.000367	0.00147	CcSEcCtD
Ziprasidone—Nausea—Vemurafenib—melanoma	0.000366	0.00147	CcSEcCtD
Ziprasidone—Thrombocytopenia—Bleomycin—melanoma	0.000365	0.00147	CcSEcCtD
Ziprasidone—Vision blurred—Temozolomide—melanoma	0.000363	0.00146	CcSEcCtD
Ziprasidone—Myalgia—Dactinomycin—melanoma	0.000363	0.00146	CcSEcCtD
Ziprasidone—Tremor—Temozolomide—melanoma	0.000361	0.00145	CcSEcCtD
Ziprasidone—Angina pectoris—Docetaxel—melanoma	0.000358	0.00144	CcSEcCtD
Ziprasidone—Leukopenia—Carmustine—melanoma	0.000357	0.00144	CcSEcCtD
Ziprasidone—Anaemia—Temozolomide—melanoma	0.000356	0.00143	CcSEcCtD
Ziprasidone—Anorexia—Bleomycin—melanoma	0.000356	0.00143	CcSEcCtD
Ziprasidone—Agitation—Temozolomide—melanoma	0.000354	0.00143	CcSEcCtD
Ziprasidone—Angioedema—Temozolomide—melanoma	0.000352	0.00142	CcSEcCtD
Ziprasidone—Hypotension—Bleomycin—melanoma	0.000349	0.0014	CcSEcCtD
Ziprasidone—Vertigo—Temozolomide—melanoma	0.000346	0.00139	CcSEcCtD
Ziprasidone—Infection—Dactinomycin—melanoma	0.000346	0.00139	CcSEcCtD
Ziprasidone—Leukopenia—Temozolomide—melanoma	0.000345	0.00139	CcSEcCtD
Ziprasidone—Hypertension—Carmustine—melanoma	0.000344	0.00139	CcSEcCtD
Ziprasidone—Palpitations—Temozolomide—melanoma	0.000341	0.00137	CcSEcCtD
Ziprasidone—Thrombocytopenia—Dactinomycin—melanoma	0.000341	0.00137	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Bleomycin—melanoma	0.00034	0.00137	CcSEcCtD
Ziprasidone—Chest pain—Carmustine—melanoma	0.00034	0.00137	CcSEcCtD
Ziprasidone—Myalgia—Carmustine—melanoma	0.00034	0.00137	CcSEcCtD
Ziprasidone—Anxiety—Carmustine—melanoma	0.000339	0.00136	CcSEcCtD
Ziprasidone—Cough—Temozolomide—melanoma	0.000336	0.00135	CcSEcCtD
Ziprasidone—Paraesthesia—Bleomycin—melanoma	0.000335	0.00135	CcSEcCtD
Ziprasidone—Weight increased—Docetaxel—melanoma	0.000335	0.00135	CcSEcCtD
Ziprasidone—Weight decreased—Docetaxel—melanoma	0.000333	0.00134	CcSEcCtD
Ziprasidone—Hypertension—Temozolomide—melanoma	0.000333	0.00134	CcSEcCtD
Ziprasidone—Dyspnoea—Bleomycin—melanoma	0.000333	0.00134	CcSEcCtD
Ziprasidone—Anorexia—Dactinomycin—melanoma	0.000332	0.00133	CcSEcCtD
Ziprasidone—Pneumonia—Docetaxel—melanoma	0.00033	0.00133	CcSEcCtD
Ziprasidone—Confusional state—Carmustine—melanoma	0.000328	0.00132	CcSEcCtD
Ziprasidone—Arthralgia—Temozolomide—melanoma	0.000328	0.00132	CcSEcCtD
Ziprasidone—Myalgia—Temozolomide—melanoma	0.000328	0.00132	CcSEcCtD
Ziprasidone—Infestation—Docetaxel—melanoma	0.000328	0.00132	CcSEcCtD
Ziprasidone—Infestation NOS—Docetaxel—melanoma	0.000328	0.00132	CcSEcCtD
Ziprasidone—Anxiety—Temozolomide—melanoma	0.000327	0.00132	CcSEcCtD
Ziprasidone—KCNH2—lymph node—melanoma	0.000326	0.00349	CbGeAlD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000326	0.00131	CcSEcCtD
Ziprasidone—Decreased appetite—Bleomycin—melanoma	0.000324	0.0013	CcSEcCtD
Ziprasidone—Infection—Carmustine—melanoma	0.000324	0.0013	CcSEcCtD
Ziprasidone—Renal failure—Docetaxel—melanoma	0.000323	0.0013	CcSEcCtD
Ziprasidone—ADRA2C—lymph node—melanoma	0.000322	0.00345	CbGeAlD
Ziprasidone—Neuropathy peripheral—Docetaxel—melanoma	0.000322	0.00129	CcSEcCtD
Ziprasidone—Dry mouth—Temozolomide—melanoma	0.000321	0.00129	CcSEcCtD
Ziprasidone—Jaundice—Docetaxel—melanoma	0.00032	0.00129	CcSEcCtD
Ziprasidone—Conjunctivitis—Docetaxel—melanoma	0.000319	0.00128	CcSEcCtD
Ziprasidone—Thrombocytopenia—Carmustine—melanoma	0.000319	0.00128	CcSEcCtD
Ziprasidone—Tachycardia—Carmustine—melanoma	0.000318	0.00128	CcSEcCtD
Ziprasidone—Confusional state—Temozolomide—melanoma	0.000317	0.00128	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000317	0.00128	CcSEcCtD
Ziprasidone—Infection—Temozolomide—melanoma	0.000313	0.00126	CcSEcCtD
Ziprasidone—HTR2A—head—melanoma	0.000312	0.00334	CbGeAlD
Ziprasidone—Anorexia—Carmustine—melanoma	0.00031	0.00125	CcSEcCtD
Ziprasidone—Epistaxis—Docetaxel—melanoma	0.00031	0.00124	CcSEcCtD
Ziprasidone—Nervous system disorder—Temozolomide—melanoma	0.000309	0.00124	CcSEcCtD
Ziprasidone—Thrombocytopenia—Temozolomide—melanoma	0.000308	0.00124	CcSEcCtD
Ziprasidone—Feeling abnormal—Bleomycin—melanoma	0.000307	0.00124	CcSEcCtD
Ziprasidone—Skin disorder—Temozolomide—melanoma	0.000306	0.00123	CcSEcCtD
Ziprasidone—Hypotension—Carmustine—melanoma	0.000304	0.00122	CcSEcCtD
Ziprasidone—Hyperhidrosis—Temozolomide—melanoma	0.000304	0.00122	CcSEcCtD
Ziprasidone—Decreased appetite—Dactinomycin—melanoma	0.000302	0.00122	CcSEcCtD
Ziprasidone—Fatigue—Dactinomycin—melanoma	0.0003	0.00121	CcSEcCtD
Ziprasidone—Anorexia—Temozolomide—melanoma	0.0003	0.00121	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Carmustine—melanoma	0.000297	0.00119	CcSEcCtD
Ziprasidone—Urticaria—Bleomycin—melanoma	0.000296	0.00119	CcSEcCtD
Ziprasidone—Haemoglobin—Docetaxel—melanoma	0.000296	0.00119	CcSEcCtD
Ziprasidone—Rhinitis—Docetaxel—melanoma	0.000295	0.00119	CcSEcCtD
Ziprasidone—Body temperature increased—Bleomycin—melanoma	0.000295	0.00119	CcSEcCtD
Ziprasidone—Hepatitis—Docetaxel—melanoma	0.000295	0.00118	CcSEcCtD
Ziprasidone—Haemorrhage—Docetaxel—melanoma	0.000295	0.00118	CcSEcCtD
Ziprasidone—Insomnia—Carmustine—melanoma	0.000295	0.00118	CcSEcCtD
Ziprasidone—Hypoaesthesia—Docetaxel—melanoma	0.000293	0.00118	CcSEcCtD
Ziprasidone—Paraesthesia—Carmustine—melanoma	0.000292	0.00118	CcSEcCtD
Ziprasidone—Pharyngitis—Docetaxel—melanoma	0.000292	0.00118	CcSEcCtD
Ziprasidone—Urinary tract disorder—Docetaxel—melanoma	0.000291	0.00117	CcSEcCtD
Ziprasidone—Dyspnoea—Carmustine—melanoma	0.00029	0.00117	CcSEcCtD
Ziprasidone—Oedema peripheral—Docetaxel—melanoma	0.00029	0.00117	CcSEcCtD
Ziprasidone—Somnolence—Carmustine—melanoma	0.00029	0.00116	CcSEcCtD
Ziprasidone—Connective tissue disorder—Docetaxel—melanoma	0.000289	0.00116	CcSEcCtD
Ziprasidone—Urethral disorder—Docetaxel—melanoma	0.000289	0.00116	CcSEcCtD
Ziprasidone—Feeling abnormal—Dactinomycin—melanoma	0.000287	0.00115	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Temozolomide—melanoma	0.000287	0.00115	CcSEcCtD
Ziprasidone—Insomnia—Temozolomide—melanoma	0.000285	0.00114	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Dactinomycin—melanoma	0.000285	0.00114	CcSEcCtD
Ziprasidone—CYP2D6—head—melanoma	0.000284	0.00304	CbGeAlD
Ziprasidone—Visual impairment—Docetaxel—melanoma	0.000284	0.00114	CcSEcCtD
Ziprasidone—Decreased appetite—Carmustine—melanoma	0.000283	0.00114	CcSEcCtD
Ziprasidone—Paraesthesia—Temozolomide—melanoma	0.000283	0.00114	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Carmustine—melanoma	0.000281	0.00113	CcSEcCtD
Ziprasidone—Dyspnoea—Temozolomide—melanoma	0.000281	0.00113	CcSEcCtD
Ziprasidone—Somnolence—Temozolomide—melanoma	0.00028	0.00113	CcSEcCtD
Ziprasidone—Constipation—Carmustine—melanoma	0.000278	0.00112	CcSEcCtD
Ziprasidone—Dyspepsia—Temozolomide—melanoma	0.000277	0.00111	CcSEcCtD
Ziprasidone—Eye disorder—Docetaxel—melanoma	0.000275	0.00111	CcSEcCtD
Ziprasidone—Abdominal pain—Dactinomycin—melanoma	0.000275	0.00111	CcSEcCtD
Ziprasidone—Body temperature increased—Dactinomycin—melanoma	0.000275	0.00111	CcSEcCtD
Ziprasidone—Hypersensitivity—Bleomycin—melanoma	0.000275	0.00111	CcSEcCtD
Ziprasidone—Decreased appetite—Temozolomide—melanoma	0.000274	0.0011	CcSEcCtD
Ziprasidone—Cardiac disorder—Docetaxel—melanoma	0.000273	0.0011	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Temozolomide—melanoma	0.000272	0.00109	CcSEcCtD
Ziprasidone—Fatigue—Temozolomide—melanoma	0.000271	0.00109	CcSEcCtD
Ziprasidone—Constipation—Temozolomide—melanoma	0.000269	0.00108	CcSEcCtD
Ziprasidone—Feeling abnormal—Carmustine—melanoma	0.000268	0.00108	CcSEcCtD
Ziprasidone—Asthenia—Bleomycin—melanoma	0.000268	0.00108	CcSEcCtD
Ziprasidone—Angiopathy—Docetaxel—melanoma	0.000267	0.00108	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Carmustine—melanoma	0.000266	0.00107	CcSEcCtD
Ziprasidone—Immune system disorder—Docetaxel—melanoma	0.000266	0.00107	CcSEcCtD
Ziprasidone—Mediastinal disorder—Docetaxel—melanoma	0.000265	0.00107	CcSEcCtD
Ziprasidone—Chills—Docetaxel—melanoma	0.000264	0.00106	CcSEcCtD
Ziprasidone—Arrhythmia—Docetaxel—melanoma	0.000263	0.00106	CcSEcCtD
Ziprasidone—HRH1—lymph node—melanoma	0.000262	0.0028	CbGeAlD
Ziprasidone—Alopecia—Docetaxel—melanoma	0.00026	0.00105	CcSEcCtD
Ziprasidone—Feeling abnormal—Temozolomide—melanoma	0.000259	0.00104	CcSEcCtD
Ziprasidone—Mental disorder—Docetaxel—melanoma	0.000258	0.00104	CcSEcCtD
Ziprasidone—Abdominal pain—Carmustine—melanoma	0.000257	0.00104	CcSEcCtD
Ziprasidone—Body temperature increased—Carmustine—melanoma	0.000257	0.00104	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Temozolomide—melanoma	0.000257	0.00104	CcSEcCtD
Ziprasidone—ADRA2A—lymph node—melanoma	0.000257	0.00275	CbGeAlD
Ziprasidone—Erythema—Docetaxel—melanoma	0.000256	0.00103	CcSEcCtD
Ziprasidone—Malnutrition—Docetaxel—melanoma	0.000256	0.00103	CcSEcCtD
Ziprasidone—Hypersensitivity—Dactinomycin—melanoma	0.000256	0.00103	CcSEcCtD
Ziprasidone—Urticaria—Temozolomide—melanoma	0.00025	0.00101	CcSEcCtD
Ziprasidone—Asthenia—Dactinomycin—melanoma	0.00025	0.001	CcSEcCtD
Ziprasidone—Abdominal pain—Temozolomide—melanoma	0.000249	0.001	CcSEcCtD
Ziprasidone—Body temperature increased—Temozolomide—melanoma	0.000249	0.001	CcSEcCtD
Ziprasidone—Back pain—Docetaxel—melanoma	0.000248	0.000998	CcSEcCtD
Ziprasidone—Muscle spasms—Docetaxel—melanoma	0.000247	0.000992	CcSEcCtD
Ziprasidone—Hypersensitivity—Carmustine—melanoma	0.00024	0.000965	CcSEcCtD
Ziprasidone—Diarrhoea—Dactinomycin—melanoma	0.000238	0.000958	CcSEcCtD
Ziprasidone—Vomiting—Bleomycin—melanoma	0.000237	0.000954	CcSEcCtD
Ziprasidone—Anaemia—Docetaxel—melanoma	0.000237	0.000953	CcSEcCtD
Ziprasidone—Rash—Bleomycin—melanoma	0.000235	0.000946	CcSEcCtD
Ziprasidone—Dermatitis—Bleomycin—melanoma	0.000235	0.000945	CcSEcCtD
Ziprasidone—Asthenia—Carmustine—melanoma	0.000234	0.00094	CcSEcCtD
Ziprasidone—Hypersensitivity—Temozolomide—melanoma	0.000232	0.000933	CcSEcCtD
Ziprasidone—Syncope—Docetaxel—melanoma	0.00023	0.000925	CcSEcCtD
Ziprasidone—Leukopenia—Docetaxel—melanoma	0.00023	0.000923	CcSEcCtD
Ziprasidone—Palpitations—Docetaxel—melanoma	0.000227	0.000912	CcSEcCtD
Ziprasidone—Asthenia—Temozolomide—melanoma	0.000226	0.000908	CcSEcCtD
Ziprasidone—Loss of consciousness—Docetaxel—melanoma	0.000225	0.000907	CcSEcCtD
Ziprasidone—Cough—Docetaxel—melanoma	0.000224	0.0009	CcSEcCtD
Ziprasidone—Diarrhoea—Carmustine—melanoma	0.000223	0.000896	CcSEcCtD
Ziprasidone—Nausea—Bleomycin—melanoma	0.000222	0.000891	CcSEcCtD
Ziprasidone—Hypertension—Docetaxel—melanoma	0.000221	0.000891	CcSEcCtD
Ziprasidone—Clozapine—CYP1B1—melanoma	0.000221	0.425	CrCbGaD
Ziprasidone—Vomiting—Dactinomycin—melanoma	0.000221	0.00089	CcSEcCtD
Ziprasidone—Rash—Dactinomycin—melanoma	0.000219	0.000882	CcSEcCtD
Ziprasidone—Myalgia—Docetaxel—melanoma	0.000218	0.000878	CcSEcCtD
Ziprasidone—Arthralgia—Docetaxel—melanoma	0.000218	0.000878	CcSEcCtD
Ziprasidone—Chest pain—Docetaxel—melanoma	0.000218	0.000878	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000217	0.000872	CcSEcCtD
Ziprasidone—Dizziness—Carmustine—melanoma	0.000215	0.000866	CcSEcCtD
Ziprasidone—Diarrhoea—Temozolomide—melanoma	0.000215	0.000866	CcSEcCtD
Ziprasidone—Dry mouth—Docetaxel—melanoma	0.000214	0.000859	CcSEcCtD
Ziprasidone—Confusional state—Docetaxel—melanoma	0.000211	0.000849	CcSEcCtD
Ziprasidone—Dizziness—Temozolomide—melanoma	0.000208	0.000837	CcSEcCtD
Ziprasidone—Infection—Docetaxel—melanoma	0.000208	0.000836	CcSEcCtD
Ziprasidone—Vomiting—Carmustine—melanoma	0.000207	0.000833	CcSEcCtD
Ziprasidone—Nausea—Dactinomycin—melanoma	0.000207	0.000831	CcSEcCtD
Ziprasidone—Shock—Docetaxel—melanoma	0.000206	0.000828	CcSEcCtD
Ziprasidone—Rash—Carmustine—melanoma	0.000205	0.000826	CcSEcCtD
Ziprasidone—Nervous system disorder—Docetaxel—melanoma	0.000205	0.000826	CcSEcCtD
Ziprasidone—Dermatitis—Carmustine—melanoma	0.000205	0.000825	CcSEcCtD
Ziprasidone—Thrombocytopenia—Docetaxel—melanoma	0.000205	0.000824	CcSEcCtD
Ziprasidone—Tachycardia—Docetaxel—melanoma	0.000204	0.000822	CcSEcCtD
Ziprasidone—Headache—Carmustine—melanoma	0.000204	0.000821	CcSEcCtD
Ziprasidone—Skin disorder—Docetaxel—melanoma	0.000203	0.000818	CcSEcCtD
Ziprasidone—Vomiting—Temozolomide—melanoma	0.0002	0.000805	CcSEcCtD
Ziprasidone—Anorexia—Docetaxel—melanoma	0.000199	0.000802	CcSEcCtD
Ziprasidone—Rash—Temozolomide—melanoma	0.000198	0.000798	CcSEcCtD
Ziprasidone—Dermatitis—Temozolomide—melanoma	0.000198	0.000797	CcSEcCtD
Ziprasidone—Headache—Temozolomide—melanoma	0.000197	0.000793	CcSEcCtD
Ziprasidone—Hypotension—Docetaxel—melanoma	0.000196	0.000787	CcSEcCtD
Ziprasidone—Nausea—Carmustine—melanoma	0.000193	0.000778	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Docetaxel—melanoma	0.000191	0.000767	CcSEcCtD
Ziprasidone—Insomnia—Docetaxel—melanoma	0.000189	0.000761	CcSEcCtD
Ziprasidone—Paraesthesia—Docetaxel—melanoma	0.000188	0.000756	CcSEcCtD
Ziprasidone—Nausea—Temozolomide—melanoma	0.000187	0.000752	CcSEcCtD
Ziprasidone—Dyspnoea—Docetaxel—melanoma	0.000187	0.00075	CcSEcCtD
Ziprasidone—Somnolence—Docetaxel—melanoma	0.000186	0.000748	CcSEcCtD
Ziprasidone—Dyspepsia—Docetaxel—melanoma	0.000184	0.000741	CcSEcCtD
Ziprasidone—Decreased appetite—Docetaxel—melanoma	0.000182	0.000732	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Docetaxel—melanoma	0.000181	0.000727	CcSEcCtD
Ziprasidone—Fatigue—Docetaxel—melanoma	0.00018	0.000726	CcSEcCtD
Ziprasidone—Constipation—Docetaxel—melanoma	0.000179	0.00072	CcSEcCtD
Ziprasidone—Feeling abnormal—Docetaxel—melanoma	0.000172	0.000694	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Docetaxel—melanoma	0.000171	0.000688	CcSEcCtD
Ziprasidone—Abdominal pain—Docetaxel—melanoma	0.000165	0.000665	CcSEcCtD
Ziprasidone—Body temperature increased—Docetaxel—melanoma	0.000165	0.000665	CcSEcCtD
Ziprasidone—Hypersensitivity—Docetaxel—melanoma	0.000154	0.00062	CcSEcCtD
Ziprasidone—Asthenia—Docetaxel—melanoma	0.00015	0.000604	CcSEcCtD
Ziprasidone—Diarrhoea—Docetaxel—melanoma	0.000143	0.000576	CcSEcCtD
Ziprasidone—Dizziness—Docetaxel—melanoma	0.000138	0.000557	CcSEcCtD
Ziprasidone—Vomiting—Docetaxel—melanoma	0.000133	0.000535	CcSEcCtD
Ziprasidone—Rash—Docetaxel—melanoma	0.000132	0.000531	CcSEcCtD
Ziprasidone—Dermatitis—Docetaxel—melanoma	0.000132	0.00053	CcSEcCtD
Ziprasidone—Headache—Docetaxel—melanoma	0.000131	0.000527	CcSEcCtD
Ziprasidone—Nausea—Docetaxel—melanoma	0.000124	0.0005	CcSEcCtD
Ziprasidone—Aripiprazole—ABCB1—melanoma	0.000118	0.227	CrCbGaD
Ziprasidone—Trazodone—ABCB1—melanoma	0.000118	0.226	CrCbGaD
Ziprasidone—Clozapine—ABCB1—melanoma	6.35e-05	0.122	CrCbGaD
Ziprasidone—CHRM3—Signaling Pathways—PTEN—melanoma	3.47e-06	1.29e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—NFKB1—melanoma	3.47e-06	1.29e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MAPK3—melanoma	3.46e-06	1.28e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CDKN1B—melanoma	3.46e-06	1.28e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MMP9—melanoma	3.46e-06	1.28e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NFKB1—melanoma	3.46e-06	1.28e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—STAT3—melanoma	3.45e-06	1.28e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MMP9—melanoma	3.45e-06	1.28e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CDKN1A—melanoma	3.45e-06	1.28e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MAPK3—melanoma	3.45e-06	1.28e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—NRAS—melanoma	3.44e-06	1.28e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PTEN—melanoma	3.44e-06	1.28e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CDKN1A—melanoma	3.44e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PTEN—melanoma	3.43e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—AKT1—melanoma	3.42e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NFKB1—melanoma	3.42e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—IL6—melanoma	3.42e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—HRAS—melanoma	3.42e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—IL6—melanoma	3.42e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—AKT1—melanoma	3.42e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MAPK1—melanoma	3.41e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EGFR—melanoma	3.41e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NFKB1—melanoma	3.41e-06	1.27e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—AKT1—melanoma	3.41e-06	1.26e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PIK3CA—melanoma	3.41e-06	1.26e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ABCB1—melanoma	3.4e-06	1.26e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—AKT1—melanoma	3.4e-06	1.26e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—IL6—melanoma	3.4e-06	1.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CASP3—melanoma	3.39e-06	1.26e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—AKT1—melanoma	3.39e-06	1.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL2—melanoma	3.39e-06	1.26e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—melanoma	3.38e-06	1.25e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—HRAS—melanoma	3.37e-06	1.25e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—IL6—melanoma	3.37e-06	1.25e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MYC—melanoma	3.37e-06	1.25e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—AKT1—melanoma	3.35e-06	1.24e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MAPK3—melanoma	3.35e-06	1.24e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MYC—melanoma	3.35e-06	1.24e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—AKT1—melanoma	3.35e-06	1.24e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.33e-06	1.24e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—PIK3CA—melanoma	3.33e-06	1.23e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—IL6—melanoma	3.32e-06	1.23e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PIK3CA—melanoma	3.31e-06	1.23e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCND1—melanoma	3.3e-06	1.22e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MAPK3—melanoma	3.3e-06	1.22e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CD—melanoma	3.3e-06	1.22e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MAPK1—melanoma	3.3e-06	1.22e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EGFR—melanoma	3.3e-06	1.22e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—PIK3CA—melanoma	3.28e-06	1.22e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MAPK1—melanoma	3.28e-06	1.22e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EGFR—melanoma	3.28e-06	1.22e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—IL6—melanoma	3.27e-06	1.21e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CTNNB1—melanoma	3.27e-06	1.21e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MYC—melanoma	3.26e-06	1.21e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ALB—melanoma	3.25e-06	1.21e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—HRAS—melanoma	3.23e-06	1.2e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—IL6—melanoma	3.23e-06	1.2e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KRAS—melanoma	3.22e-06	1.2e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—melanoma	3.22e-06	1.19e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—melanoma	3.21e-06	1.19e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MYC—melanoma	3.21e-06	1.19e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MMP9—melanoma	3.2e-06	1.19e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CDKN1A—melanoma	3.19e-06	1.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MAPK1—melanoma	3.19e-06	1.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EGFR—melanoma	3.19e-06	1.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PTEN—melanoma	3.19e-06	1.18e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—STAT3—melanoma	3.18e-06	1.18e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CG—melanoma	3.18e-06	1.18e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—NRAS—melanoma	3.18e-06	1.18e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—melanoma	3.17e-06	1.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NFKB1—melanoma	3.17e-06	1.18e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—melanoma	3.16e-06	1.17e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—melanoma	3.16e-06	1.17e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—AKT1—melanoma	3.16e-06	1.17e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—AKT1—melanoma	3.15e-06	1.17e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—melanoma	3.15e-06	1.17e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MAPK1—melanoma	3.14e-06	1.16e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EGFR—melanoma	3.14e-06	1.16e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—melanoma	3.14e-06	1.16e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—AKT1—melanoma	3.13e-06	1.16e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—STAT3—melanoma	3.13e-06	1.16e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PRKCA—melanoma	3.13e-06	1.16e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—STAT3—melanoma	3.13e-06	1.16e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—NRAS—melanoma	3.12e-06	1.16e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—NRAS—melanoma	3.12e-06	1.16e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—STAT3—melanoma	3.12e-06	1.16e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KRAS—melanoma	3.11e-06	1.15e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—AKT1—melanoma	3.11e-06	1.15e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—NRAS—melanoma	3.11e-06	1.15e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—melanoma	3.11e-06	1.15e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—STAT3—melanoma	3.11e-06	1.15e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ERCC2—melanoma	3.1e-06	1.15e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NRAS—melanoma	3.1e-06	1.15e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—melanoma	3.1e-06	1.15e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KRAS—melanoma	3.1e-06	1.15e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—IL6—melanoma	3.09e-06	1.15e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—HRAS—melanoma	3.08e-06	1.14e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—STAT3—melanoma	3.08e-06	1.14e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NRAS—melanoma	3.07e-06	1.14e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—AKT1—melanoma	3.07e-06	1.14e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—STAT3—melanoma	3.07e-06	1.14e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PPARG—melanoma	3.07e-06	1.14e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NRAS—melanoma	3.06e-06	1.13e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MAPK3—melanoma	3.04e-06	1.13e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—HRAS—melanoma	3.04e-06	1.13e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—AKT1—melanoma	3.02e-06	1.12e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KRAS—melanoma	3.01e-06	1.12e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MAPK3—melanoma	2.99e-06	1.11e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MAPK3—melanoma	2.99e-06	1.11e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—AKT1—melanoma	2.98e-06	1.1e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MAPK3—melanoma	2.98e-06	1.1e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MAPK3—melanoma	2.97e-06	1.1e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KRAS—melanoma	2.96e-06	1.1e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—PIK3CA—melanoma	2.96e-06	1.1e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MYC—melanoma	2.96e-06	1.1e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—IL6—melanoma	2.95e-06	1.09e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MAPK3—melanoma	2.94e-06	1.09e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MAPK3—melanoma	2.93e-06	1.09e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PIK3CA—melanoma	2.93e-06	1.09e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MYC—melanoma	2.91e-06	1.08e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—IL6—melanoma	2.91e-06	1.08e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MYC—melanoma	2.9e-06	1.08e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MYC—melanoma	2.89e-06	1.07e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MAPK1—melanoma	2.89e-06	1.07e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EGFR—melanoma	2.89e-06	1.07e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MYC—melanoma	2.89e-06	1.07e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—melanoma	2.88e-06	1.07e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CB—melanoma	2.87e-06	1.07e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—melanoma	2.87e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PIK3CA—melanoma	2.86e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MYC—melanoma	2.86e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—AKT1—melanoma	2.85e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MYC—melanoma	2.85e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—STAT3—melanoma	2.85e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MAPK1—melanoma	2.85e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTGS2—melanoma	2.85e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EGFR—melanoma	2.85e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PIK3CA—melanoma	2.85e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NRAS—melanoma	2.84e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MAPK1—melanoma	2.84e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EGFR—melanoma	2.84e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MAPK1—melanoma	2.83e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EGFR—melanoma	2.83e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MAPK1—melanoma	2.82e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EGFR—melanoma	2.82e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MAPK1—melanoma	2.8e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EGFR—melanoma	2.8e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CD—melanoma	2.79e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MAPK1—melanoma	2.79e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EGFR—melanoma	2.79e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—AKT1—melanoma	2.78e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PIK3CA—melanoma	2.77e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—melanoma	2.77e-06	1.03e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ALB—melanoma	2.76e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—melanoma	2.75e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—HRAS—melanoma	2.74e-06	1.02e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KRAS—melanoma	2.73e-06	1.01e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PIK3CA—melanoma	2.72e-06	1.01e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MAPK3—melanoma	2.72e-06	1.01e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—AKT1—melanoma	2.72e-06	1.01e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—AKT1—melanoma	2.7e-06	1e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KRAS—melanoma	2.69e-06	9.97e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PIK3CA—melanoma	2.69e-06	9.97e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KRAS—melanoma	2.68e-06	9.95e-06	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—AKT1—melanoma	2.68e-06	9.94e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—melanoma	2.68e-06	9.93e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KRAS—melanoma	2.67e-06	9.92e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KRAS—melanoma	2.67e-06	9.89e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MYC—melanoma	2.65e-06	9.82e-06	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—HRAS—melanoma	2.65e-06	9.81e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KRAS—melanoma	2.64e-06	9.79e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—melanoma	2.63e-06	9.77e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KRAS—melanoma	2.63e-06	9.77e-06	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HRAS—melanoma	2.63e-06	9.76e-06	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—IL6—melanoma	2.62e-06	9.73e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MAPK1—melanoma	2.59e-06	9.61e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EGFR—melanoma	2.59e-06	9.61e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HRAS—melanoma	2.56e-06	9.5e-06	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—IL6—melanoma	2.53e-06	9.39e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HRAS—melanoma	2.52e-06	9.35e-06	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL6—melanoma	2.52e-06	9.34e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PIK3CA—melanoma	2.51e-06	9.31e-06	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTEN—melanoma	2.48e-06	9.21e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PIK3CA—melanoma	2.47e-06	9.16e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PIK3CA—melanoma	2.47e-06	9.14e-06	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PIK3CA—melanoma	2.46e-06	9.14e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PIK3CA—melanoma	2.46e-06	9.12e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CG—melanoma	2.45e-06	9.09e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL6—melanoma	2.45e-06	9.09e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PIK3CA—melanoma	2.45e-06	9.09e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KRAS—melanoma	2.45e-06	9.07e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CB—melanoma	2.43e-06	9.03e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—melanoma	2.43e-06	9.01e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PIK3CA—melanoma	2.43e-06	9e-06	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—AKT1—melanoma	2.42e-06	8.98e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PIK3CA—melanoma	2.42e-06	8.97e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTGS2—melanoma	2.41e-06	8.95e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL6—melanoma	2.41e-06	8.95e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—AKT1—melanoma	2.39e-06	8.88e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—melanoma	2.39e-06	8.87e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—melanoma	2.39e-06	8.85e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—melanoma	2.38e-06	8.82e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—melanoma	2.37e-06	8.79e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PPARG—melanoma	2.37e-06	8.78e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—melanoma	2.35e-06	8.7e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—melanoma	2.34e-06	8.68e-06	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—AKT1—melanoma	2.34e-06	8.67e-06	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—AKT1—melanoma	2.32e-06	8.62e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HRAS—melanoma	2.32e-06	8.62e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—HRAS—melanoma	2.29e-06	8.48e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HRAS—melanoma	2.28e-06	8.46e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HRAS—melanoma	2.27e-06	8.43e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HRAS—melanoma	2.27e-06	8.41e-06	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—AKT1—melanoma	2.26e-06	8.39e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PIK3CA—melanoma	2.25e-06	8.34e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HRAS—melanoma	2.24e-06	8.32e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HRAS—melanoma	2.24e-06	8.3e-06	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—AKT1—melanoma	2.22e-06	8.25e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL6—melanoma	2.22e-06	8.25e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—AKT1—melanoma	2.2e-06	8.15e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL6—melanoma	2.19e-06	8.11e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL6—melanoma	2.18e-06	8.1e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL6—melanoma	2.18e-06	8.07e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—melanoma	2.17e-06	8.07e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL6—melanoma	2.17e-06	8.05e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CD—melanoma	2.16e-06	7.99e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL6—melanoma	2.15e-06	7.97e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL6—melanoma	2.14e-06	7.95e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ALB—melanoma	2.13e-06	7.89e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTEN—melanoma	2.1e-06	7.8e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HRAS—melanoma	2.08e-06	7.71e-06	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—AKT1—melanoma	2.05e-06	7.61e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—AKT1—melanoma	2.02e-06	7.49e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—AKT1—melanoma	2.01e-06	7.47e-06	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—AKT1—melanoma	2.01e-06	7.46e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—AKT1—melanoma	2.01e-06	7.45e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—AKT1—melanoma	2e-06	7.42e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL6—melanoma	1.99e-06	7.38e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—AKT1—melanoma	1.98e-06	7.35e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—AKT1—melanoma	1.98e-06	7.33e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CB—melanoma	1.88e-06	6.97e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTGS2—melanoma	1.86e-06	6.9e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—AKT1—melanoma	1.84e-06	6.81e-06	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CA—melanoma	1.75e-06	6.5e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTEN—melanoma	1.62e-06	6.02e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CA—melanoma	1.48e-06	5.5e-06	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—AKT1—melanoma	1.43e-06	5.31e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—AKT1—melanoma	1.21e-06	4.5e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CA—melanoma	1.15e-06	4.25e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—AKT1—melanoma	9.36e-07	3.47e-06	CbGpPWpGaD
